Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Toronto
$105,000.00
Characterizing the anti-cancer activity and clinical use of Tigecycline for patients with leukemia
EF 2009-10
Résumé
Tigecycline is an antibiotic used to treat skin and intraabdominal infections. Recently, we have identified Tigecycline as a novel anti-cancer agent with selectivity for cancerous cells in leukemia. The goal of this research is to advance the health care options for patients with leukemia. We propose to fulfill this goal by performing pre-clinical experiments and then initiating a phase I clinical trail with tigecycline.
The first goal of this research is to explore the mechanism of tigecycline action against cancer cells. We will carry out experiments to determine the mechanism of inhibiting the protein machinery inside a cell and how this results in cell death. Furthermore, our focus will also be to examine if cancerous cells have higher rates of protein production than normal cells highlighting this as a possible new target for anti-cancer drug design.
The second goal of this research is to prepare tigecycline for use in patients with leukemia. We have seen that tigecycline is toxic to cancerous cells from the blood of patients of leukemia, and not toxic to cells from the blood of normal donors. Further experiments will be carried out in cell culture and mouse models to determine the effective dose where toxicity is selective for cancerous cells before proceeding to clinical trial. Past clinical studies have looked at tigecycline's toxicity and metabolism in normal healthy volunteers as an antibiotic, therefore we will be able to rapidly initiate first phase clinical trials in patients with end-stage leukemia.
This overall goal of this research is to move tigecycline from the scientific laboratory to patient care. Also, we will explore the mechanism of toxic action against cancer cells, enabling future cancer research to target similar pathways. This research aims to improve the care of patients suffering from leukemia, and possibly provide future insight into further anti-cancer therapeutics in Canada.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
206210
Name
Skrtic Marko
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Characterizing the anti-cancer activity and clinical use of Tigecycline for patients with leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Novel Leukemia Therapeutic; On And Off-Patent Drug Screening; Translational Research
Abstract
Tigecycline is an antibiotic used to treat skin and intraabdominal infections. Recently, we have identified Tigecycline as a novel anti-cancer agent with selectivity for cancerous cells in leukemia. The goal of this research is to advance the health care options for patients with leukemia. We propose to fulfill this goal by performing pre-clinical experiments and then initiating a phase I clinical trail with tigecycline.
The first goal of this research is to explore the mechanism of tigecycline action against cancer cells. We will carry out experiments to determine the mechanism of inhibiting the protein machinery inside a cell and how this results in cell death. Furthermore, our focus will also be to examine if cancerous cells have higher rates of protein production than normal cells highlighting this as a possible new target for anti-cancer drug design.
The second goal of this research is to prepare tigecycline for use in patients with leukemia. We have seen that tigecycline is toxic to cancerous cells from the blood of patients of leukemia, and not toxic to cells from the blood of normal donors. Further experiments will be carried out in cell culture and mouse models to determine the effective dose where toxicity is selective for cancerous cells before proceeding to clinical trial. Past clinical studies have looked at tigecycline's toxicity and metabolism in normal healthy volunteers as an antibiotic, therefore we will be able to rapidly initiate first phase clinical trials in patients with end-stage leukemia.
This overall goal of this research is to move tigecycline from the scientific laboratory to patient care. Also, we will explore the mechanism of toxic action against cancer cells, enabling future cancer research to target similar pathways. This research aims to improve the care of patients suffering from leukemia, and possibly provide future insight into further anti-cancer therapeutics in Canada.
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Skrtic, Marko
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~